Artivion Corp (AORT) Enterprise Value to EBITDA Ratio

Artivion, Inc. (AORT) develops advanced cardiovascular biomaterials, actively expanding R&D in the field of aortic implants. The EV/EBITDA multiple of this capital-intensive business reflects market expectations, where 26.15 serves as the final level marker. Unwavering surgeon confidence in the brand and an aging population guarantee stable demand for the company's products regardless of economic crises.
Comprehensive metric breakdowns and analytics for CryoLife (AORT)

This indicator compares the total value of assets and debts with operating profit before depreciation and amortization, determining the real value of the business regardless of the tax regime. By analyzing the business valuation of Artivion, Inc. (AORT) through EV/EBITDA trends, an investor can see how the number of cardiac surgeries and regulatory approvals for new biomaterials impact the company's capitalization efficiency relative to its debt load.